ArticleNature2021
Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 234 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
234citing papers in PubMed, 1 pooled it
36.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
234 citing papers in PubMed, 1 synthesis or guideline pooled it, 380 citations in OpenAlex.
- The association between tumor-stromal collagen features and the clinical outcomes of patients with breast cancer: a systematic review.Breast cancer research : BCR · 2025Pooled it
- The haunted Umwelt: a biosemiotic and hauntological account of immune semiotic corruption in field cancerization.Theory in biosciences = Theorie in den Biowissenschaften · 2026Article
- Targeting receptor tyrosine kinases: from molecular mechanisms to clinical therapeutics.Signal transduction and targeted therapy · 2026Review
- Review
- Understanding and targeting the tumour matrisome.Nature reviews. Clinical oncology · 2026Review
- The spatial architecture of tumor immunity: Emerging predictive biomarkers across cancer.Immunologic research · 2026Review
- Extracellular Matrix Remodeling in Tumors: Forces Beyond Fibroblasts.Cancer research · 2026Article
- Supermeres Containing the Discoidin Domain Receptor 1 Extracellular Domain Promote Collagen Alignment and Immune Exclusion in Microsatellite-Stable Colorectal Cancer.Cancer research communications · 2026Article
- Icaritin Sensitizes Hepatocellular Carcinoma to PD-L1 Therapy by NQO1-Dependent Ferroptosis Induction.Phytotherapy research : PTR · 2026Article
- Spatial ecotype in tumor immune exclusion: from spatial architecture to therapeutic strategies.Molecular cancer · 2026Review
- Computational Pathology Reveals Extracellular-Matrix Imaging Biomarkers of Therapy Response in Preclinical Breast Cancer.Cancers · 2026Article
- Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance.Journal of experimental & clinical cancer research : CR · 2026Review
- Review
- The CD49b (ITGA2) collagen receptor excludes CD8iScience · 2026Article
- Mechanobiology of CAR-T cell therapy: regulatory mechanisms and strategies for enhanced antitumor immunity.Journal of translational medicine · 2026Review
- The DDR1 Tyrosine Kinase Promotes Th17 Cell Migration in Three-Dimensional Collagen and into the Joints During Inflammatory Arthritis.International journal of molecular sciences · 2026Article
- Targeting the Barriers Driving Immune Exclusion.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Piezobiomimetic delivery nanosystem converts cold tumors to hot by parallel PANoptosis/STING activation in hepatocellular carcinoma.Science advances · 2026Article
- Hypoxia and lactate metabolism-related gene COL5A3 promotes triple negative breast cancer progression via DDR1/FAK/PI3K/AKT pathway.Biology direct · 2026Article
- DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL33-Mediated M2-like Polarization of Tumor-Associated Macrophages.Cancer immunology research · 2026Article
174 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
31 authors at 5 institutions in 2 countries.
Xiujie Sun *Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
Bogang Wu *Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.ORCID http://orcid.org/0000-0003-1654-198X
Huai-Chin Chiang *Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.ORCID http://orcid.org/0000-0002-7616-3362
Hui DengTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Xiaowen ZhangDepartment of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
Wei XiongTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Junquan LiuTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Aaron M RozeboomLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Brent T HarrisLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Eline BlommaertProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0003-0040-5158
Antonio GomezRheumatology Department and Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain.ORCID http://orcid.org/0000-0001-5308-981X
Roderic Espin GarciaProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2494-0964
Yufan ZhouDepartment of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.ORCID http://orcid.org/0000-0002-8385-433X
Payal MitraDepartment of Anatomy and Cell Biology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
Madeleine PrevostDepartment of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
Deyi ZhangDepartment of Medicine, The Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA.
Debarati BanikDepartment of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
Claudine IsaacsLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Deborah BerryLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Catherine LaiLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Krysta ChaldekasLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Patricia S LathamDepartment of Pathology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.ORCID http://orcid.org/0000-0003-2782-9444
Christine A BrantnerGW Nanofabrication and Imaging Center, The George Washington University, Washington, DC, USA.
Anastas PopratiloffGW Nanofabrication and Imaging Center, The George Washington University, Washington, DC, USA.
Victor X JinDepartment of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.ORCID http://orcid.org/0000-0002-8765-3471
Ningyan ZhangTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID http://orcid.org/0000-0002-4348-2180
Yanfen HuDepartment of Anatomy and Cell Biology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
Miguel Angel PujanaProCURE, Catalan Institute of Oncology, Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain. mapujana@iconcologia.net.ORCID http://orcid.org/0000-0003-3222-4044
Tyler J CurielDepartment of Medicine, The Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA. curielt@uthscsa.edu.ORCID http://orcid.org/0000-0001-6962-9411
Zhiqiang AnTexas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA. Zhiqiang.An@uth.tmc.edu.ORCID http://orcid.org/0000-0001-9309-2335
Rong LiDepartment of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA. rli69@gwu.edu.ORCID http://orcid.org/0000-0002-6471-6580
George Washington University · USGeorgetown University · USBrown Foundation · USThe University of Texas Health Science Center at San Antonio · USBellvitge University Hospital · ES
Funding
Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5MTISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1MNeurobehavioral Evaluation CoreP50HD105328 · NICHD · CHILDREN'S RESEARCH INSTITUTE · PI WILLIAM Davis GAILLARD · 2021 to 2026
$9.3M(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltrationR01CA205965 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI REEVES, WILLIAM BRIAN · 2017 to 2021
$3.2MOmics analysis of three-dimensional transcriptional regulationR01GM114142 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI JIN, VICTOR, LIN, SHILI · 2015 to 2024
$2.7MRegulation of ER-beta Signaling in CarcinogenesisR01CA206529 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CURIEL, TYLER J., LI, RONG · 2017 to 2021
$2.4MBoosting Antitumor Immunity by Blocking Both Tumor and Adipose DDR1R01CA246707 · NCI · GEORGE WASHINGTON UNIVERSITY · PI LI, RONG · 2020 to 2024
$2.3MRole of BRCA1 phosphorylation in DNA DSB repair and genome stability maintenanceR01CA212674 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HU, YANFEN, LI, RONG · 2017 to 2022
$1.9MHigh Throughput DNA Sequencer: Illumina HiSeq 3000 SequencerS10OD021805 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2016 to 2016
$600kNCI NIH HHS P30 CA051008NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA205965NCI NIH HHS R01 CA206529NCI NIH HHS R01 CA212674NCI NIH HHS R01 CA246707NICHD NIH HHS P50 HD105328NIGMS NIH HHS R01 GM114142NIH HHS S10 OD021805
Abstract
Immune exclusion predicts poor patient outcomes in multiple malignancies, including triple-negative breast cancer (TNBC)
Indexed as
Tumor EscapeAnimalsCell Line, TumorCollagenDiscoidin Domain Receptor 1Disease Models, AnimalExtracellular MatrixFemaleGene DeletionGene Knockout TechniquesHumansImmunocompetenceImmunotherapyMiceT-LymphocytesTriple Negative Breast NeoplasmsCollagenDDR1 protein, humanDdr1 protein, mouseDiscoidin Domain Receptor 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.